Price
No data yet.
Social Signal Score
Analyst Ratings
12 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ram Aiyar
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 57
- Beta
- 2.25
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -3.37
Financials
Revenue
$0.00-100.0%Net Income
$-18.92MEBITDA
$-19.75MFree Cash Flow
$-17.03MEPS (diluted)
$-1.07Shares Outstanding (diluted)
17.62M+2761.5%Operating Expenses
$20.11MCash & Debt
$115.04MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $6.39M | $-117.26M | $-12.48 |
| 2024 | $2.27M | $-83.58M | $-9.37 |
| 2023 | $0.00 | $-81.17M | $-53.09 |
| 2022 | $0.00 | $-58.03M | $-227.58 |
| 2021 | $0.00 | $-21.96M | $-4.94 |
| 2020 | $36.98M | $-26.51M | $-41.10 |
| 2019 | $28.95M | $-18.75M | $-30.39 |
| 2018 | $0.00 | $-19.17M | $-30.57 |
| 2017 | $0.00 | $-20.24M | $-32.27 |
Valuation
KRROhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120-5.26%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·18h ago·Positive
Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121 CAMBRIDGE, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging its oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, announced today that the first cohort of participants has been dosed in its Phase 1/2 clinical trial for KRRO-121, the Comp…
View source ↗ - Newsglobenewswire.com·40d ago·Neutral
Korro to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced that Ram Aiyar, President & Chief Executive Officer will participate in the following investor conferences:
View source ↗ - Newszacks.com·56d ago·Positive
All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy Korro Bio, Inc. (KRRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-1.25 per share
Typical surprise +3.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-1.07 vs $-1.34beat
- Thu, May 7$-1.69 vs $-1.60miss
- Thu, Mar 12$-5.32 vs $-1.93miss
- Wed, Nov 12$-1.92 vs $-2.61beat
- Tue, Aug 12$-2.74 vs $-2.54miss
- Wed, May 7$-2.49 vs $-2.60beat
Estimates and results for KRRO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by KRRO officers and directors.
- Bought
- $20.8m
- Sold
- $5.8m
21 trades
34 trades
- Formela Jean Francoissold
- Formela Jean Francoissold
- Formela Jean Francoissold
- Formela Jean Francoissold
- Dolan Oliversold
- Dolan Oliversold
- Dolan Oliversold
- Formela Jean Francoissold
45 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in KRRO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.